We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 26, 2021

No Benefit of Postoperative Dalteparin Bridging Treatment for Preventing Thromboembolism

BMJ : British Medical Journal

 

Additional Info

BMJ : British Medical Journal
Postoperative Low Molecular Weight Heparin Bridging Treatment for Patients at High Risk of Arterial Thromboembolism (PERIOP2): Double Blind Randomised Controlled Trial
BMJ 2021 Jun 09;[EPub Ahead of Print], MJ Kovacs, PS Wells, DR Anderson, A Lazo-Langner, C Kearon, SM Bates, M Blostein, SR Kahn, S Schulman, E Sabri, S Solymoss, T Ramsay, E Yeo, MA Rodger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading